Skip to main content

Latest Market News — Page 178

Page 178 · 30 stories scored 7+ · newest 7:30 AM ET · How scores work

Thu, Oct 1530 stories
7MANManpowerGroup Inc.ManpowerGroup Posts Q3 EPS of $0.71Earnings & guidance · Dow Jones Newswires● Neutral8SCHWSCHWAB CHARLES CORPSchwab Posts $2.9B Q3 Profit, Extending Record Earnings StreakEarnings & guidance · Dow Jones Newswires▲ PositivePro7USBU.S. BancorpU.S. Bancorp Beats on Q3 EPS, Raises Full-Year Revenue and Operating Leverage GuidanceEarnings & guidance · Seeking Alpha▲ Positive7DELLDell Technologies Inc.Dell Sinks 11% as Barclays Downgrade Questions AI Server GrowthOwnership & investors · Coinpedia▼ Negative7BEEMBeam GlobalBeam Global Jumps 16% as Pending Acquisition ScoutDI Lands Nuclear OrderM&A & partnerships · Seeking Alpha▲ Positive7MANManpowerGroup Inc.ManpowerGroup Names Becky Frankiewicz CEO as Prising Moves to Executive ChairExecutive changes · PR Newswire● Neutral9PAGPenske Automotive Group, Inc.Penske Automotive Signs $212/Share Take-Private Deal at $16.3B Enterprise ValueM&A & partnerships · Dow Jones Newswires▲ PositivePro7USBU.S. BancorpU.S. Bancorp Q3 Revenue Edges Past Estimates as EPS Climbs 10%Earnings & guidance · Reuters▼ Negative7TSLATesla, Inc.Barclays Floats All-Stock SpaceX-Tesla Merger Within WeeksM&A & partnerships · Dow Jones Newswires● Neutral7KMBKimberly-Clark CorporationKimberly-Clark Guides 2026 Organic Sales Growth Below Category AverageEarnings & guidance · Dow Jones Newswires▼ Negative7CLMTCalumet, Inc.Calumet Calls $150M of 9.75% Notes, Trims $265M Debt Since JulyFinancing · PR Newswire▲ Positive7KRYSKrystal Biotech, Inc.KB113 Wipes Out Basal Cell Tumors in Gorlin Syndrome Pilot, Including Non-Injected LesionsProduct & regulatory · GlobeNewswire▲ Positive7PLUGPlug Power Inc.Plug Power Pre-Announces Q3 Revenue Growth Above 10%, Cash Burn Falls to $28MEarnings & guidance · GlobeNewswire▲ Positive7ANLAdlai Nortye Group Ltd.Adlai Nortye Taps Lilly and Merck KGaA to Supply Cetuximab for AN4035 Combination TrialM&A & partnerships · GlobeNewswire▲ Positive7CRGOFreightos LtdFreightos Q3 Platform KPIs Beat Guidance: Transactions Up 15%, GBV Up 30%Earnings & guidance · PR Newswire▲ Positive7MAINMain Street Capital CorporationMain Street Guides Q3 NII to $0.87-$0.91, NAV Up for 17th Straight QuarterEarnings & guidance · PR Newswire▲ Positive7CRONCronos Group Inc.Cronos Closes €57.5M CanAdelaar Deal, Takes Europe's Largest Adult-Use Cannabis PlatformM&A & partnerships · GlobeNewswire▲ Positive8AQSTAquestive Therapeutics, Inc.FDA Accepts Anaphylm NDA Resubmission, Sets March 16, 2027 Decision DateProduct & regulatory · GlobeNewswire▲ PositivePro7HLNEHamilton Lane IncorporatedHamilton Lane Elevates Chairman Hartley Rogers to Co-CEO, Shifts Erik HirschExecutive changes · Dow Jones Newswires● Neutral7MRSHMarsh & McLennan Companies, Inc.Marsh & McLennan Consulting Revenue Jumps 9% in Q3Earnings & guidance · Dow Jones Newswires▲ Positive7OPENAIOpenAIOpenAI Backs Industry Slowdown as Zuckerberg, Huang Push Back on AI RulesProduct & regulatory · Reuters● Neutral7SSNLFSamsung ElectronicsMusk's China RAM Warning Deepens Memory Glut Fears; Samsung Falls 9.5%, SK Hynix 11.1%Legal & risk · Benzinga▼ Negative7USBU.S. BancorpU.S. Bancorp Releases Q3 2026 Results, Call Set for 8 a.m. CTEarnings & guidance · BusinessWire● Neutral7CMCCommercial Metals CompanyCommercial Metals Posts 4Q EPS of $1.91Earnings & guidance · Dow Jones Newswires● Neutral7PNCPNC FINANCIAL SERVICES GROUP, INC.PNC Q3 Revenue and Net Interest Income Edge Past Estimates, EPS Hits $4.97Earnings & guidance · Reuters▼ Negative7PNCPNC FINANCIAL SERVICES GROUP, INC.PNC Posts $4.2B Q3 Net Interest IncomeEarnings & guidance · Dow Jones Newswires● Neutral8OPENAIOpenAIEight Red States Sue OpenAI Over ChatGPT Safety, Seek Penalties and AI Development LimitsLegal & risk · Benzinga▼ NegativePro8BNYBank of New York Mellon CorpBNY Posts $2.34 Q3 EPS, Up 24% on 12% Revenue GrowthEarnings & guidance · Dow Jones Newswires▲ PositivePro8FHNFirst Horizon CorpFirst Horizon Swings to $94M Loss on $4.5B Mortgage Sale, Adjusted EPS $0.53Earnings & guidance · PR Newswire● NeutralPro7VNDAVanda Pharmaceuticals Inc.Vanda Shelves Anxiety Drug Program After Phase III MissProduct & regulatory · Seeking Alpha▼ Negative
How Wiseek picks and scores these

How Wiseek curates this list

Every entry started life as licensed wire-service reporting (Reuters, Dow Jones Newswires, and similar publishers) covering ticker-attributable events. Wiseek's editorial pipeline ingests these in real time, runs each headline through our domain-tuned importance scorer, and surfaces only items rated 7 or higher on a 1–10 market-impact scale. Items below 7 are filtered out at the database query so the public feed stays signal-dense.

What "AI-ranked analysis" means

For each item we publish a plain-English summary, a sentiment label (positive / negative / neutral), and a structured list of key events extracted from the underlying source. Score, summary, and sentiment come from Wiseek's in-house models — not generic chatbot output. See our methodology for the full pipeline and our editorial policy for source-attribution standards.

What's not on this page

Generic market commentary, opinion columns, low-impact press releases, and items below the 7-point importance threshold. Wiseek aggregates and scores wire-service headlines; the underlying publishers retain their original reporting and are credited per article.

Track by company

Follow SEC filings and market news for a specific company by visiting its ticker page: AAPL, MSFT, NVDA, TSLA, AMZN, GOOGL, META, JPM, V, UNH, XOM, AVGO, LLY, MA, COST, JNJ, PG, HD, ABBV, MRK, KO, NFLX, AMD, WMT, CVX, BAC — or browse all covered tickers.